Figure 3

Effect of treatment with a selective CXCR2 inhibitor on lung inflammation and tumor promotion. (A) Total and lineage-specific leukocyte number in BALF of CC-LR mice treated or non-treated with SBZ (selective CXCR2 inhibitor) at the age of 14 weeks (mean ± SE; * = P ≤ 0.05 for CC-LR vs CC-LR plus SBZ). (B) Total and lineage-specific leukocyte number in BALF of NTHi-exposed CC-LR mice treated or non-treated with SBZ collected 1 day after last NTHi aerosol exposure at the age of 14 weeks. (C) Real-time Q-PCR analysis of RNA extracted from whole lung tissue for relative mRNA expression of arginase 1 (normalized to GAPDH expression level, mean ± SE; * = P ≤ 0.05 for CC-LR vs CC-LR plus SBZ treatment in figure D, # = P ≤ 0.05 for CC-LR with NTHi exposure versus CC-LR with NTHi exposure plus SBZ treatment). (D) Western blot analysis of arginase 1 on the protein extracted from whole lung tissue. (E) Lung surface tumor number after SBZ treatment in NTHi exposed or unexposed CC-LR mice. (mean ± SE; * = P ≤ 0.05 for CC-LR vs CC-LR plus SBZ treatment, # = P ≤ 0.05 for CC-LR with NTHi exposure vs CC-LR with NTHi exposure plus SBZ treatment). (F) Histopathological appearance of lung tissue after treatment with SBZ in NTHi exposed or unexposed CC-LR mice (4× magnification, scale bar = 50 mm, applicable to all panels).